14 March 2019 - Public comment period now open until 10 April 2019; requests to make oral comment during public meeting also being accepted.
The Institute for Clinical and Economic Review (ICER) today released a draft evidence report assessing the clinical effectiveness and value of siponimod (Mayzent, Novartis) for the treatment of secondary progressive multiple sclerosis (SPMS).
This draft report will be open to public comment until 5pm ET on 10 April 2019. Based on stakeholder feedback, ICER may revise key assumptions and findings for its Evidence Report, which will be published on 2 May 2019. The Evidence Report will be subject to deliberation during a public meeting of the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), one of ICER's three independent evidence appraisal committees, on 23 May 2019.